RxDoctor Payments Data

Oscar Galindo

Physician Assistant · Cudahy, CANPI 1639325178

Payments from drug & device makers

$11,665in general payments, 2019–2025

Across 427 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Amgen$1000
  • Johnson & Johnson$820
  • AbbVie$752
  • GSK$729
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$11,665100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,665 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$24,091
Medicare patients
41
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol71$68,193
OzempicSemaglutide43$54,673
JardianceEmpagliflozin36$42,129
XareltoRivaroxaban21$30,571
KerendiaFinerenone19$28,399
Repatha SureclickEvolocumab18$21,070
RybelsusSemaglutide13$20,561
Dexlansoprazole DrDexlansoprazole55$17,891
TrulicityDulaglutide14$17,846
EliquisApixaban14$16,360
MounjaroTirzepatide12$16,123
Synjardy XrEmpagliflozin/Metformin Hcl14$14,363
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$14,320
JanuviaSitagliptin Phosphate13$12,721
Diclofenac Sodium42$11,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,481$75,23456 claims
AstraZenecaFarxiga$1,108$68,19371 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr$390$67,18470 claims
Lilly USA, LLCTrulicity, Mounjaro$566$33,96826 claims
Johnson & JohnsonXarelto$820$30,57121 claims
BayerKerendia$528$28,39919 claims
PfizerEliquis$245$16,36014 claims
GSKTrelegy Ellipta$729$14,32024 claims
MerckJanuvia$328$12,72113 claims
AbbVieLinzess$752$7,73513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Cudahy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →